Close

Alnylam and Ascletis collaborate to develop ALN-VSP for liver cancers in China

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Revolutionizing Pharma Manufacturing with Biofermentation

Synthetic Chemistry and Integrated Biofermentation Transformational Pharmaceutical Manufacturing Combining biofermentation...

Thermo Fisher Launches Adolescent Alopecia Areata Registry

Thermo Fisher Scientific Inc., the global leader in serving...

Alnylam Pharmaceuticals and Ascletis Pharmaceuticals have entered into a partnership to develop a systemically delivered RNAi therapeutic, ALN-VSP, for the treatment of liver cancers including hepatocellular carcinoma (HCC).

Under the agreement, Ascletis gained an exclusive license from Alnylam to develop and commercialise ALN-VSP in China including Hong Kong, Macau and Taiwan, while Alnylam retains all rights in the rest of the world, and is eligible to obtain milestones and royalties based on product sales.

Ascletis will advance ALN-VSP into a Phase II study for the treatment of HCC. Alnylam may use the data generated in China by Ascletis for development of ALN-VSP in the rest of the world for which Ascletis may potentially receive sublicense payments. Futher financial details were not disclosed.

Alnylam senior vice president and chief business officer Laurence Reid said Ascletis has the appropriate expertise in place to advance ALN-VSP through that region’s clinical and regulatory system.

“With this collaboration, we are able to develop ALN-VSP globally through the product’s advancement in a region where HCC is a particular challenge,” Reid added.

ALN-VSP has completed a Phase I study in patients with advanced malignancy with liver involvement and patients that achieved stable disease or better have been enrolled into an extension study.

Latest stories

Related stories

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Revolutionizing Pharma Manufacturing with Biofermentation

Synthetic Chemistry and Integrated Biofermentation Transformational Pharmaceutical Manufacturing Combining biofermentation...

Thermo Fisher Launches Adolescent Alopecia Areata Registry

Thermo Fisher Scientific Inc., the global leader in serving...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back